EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects

Sawar Khan, Ayesha Nisar, Xiaoxu Li, Hao Yu, Abdul Qadeer, Sardar Azhar Mehmood, Imane Lamraoui, Sijie Liu, Lipeng Zhu, Xu Deng, Bo Kong, Kejun Zhong, Zanxian Xia

MedComm · 2026-11 · 7 (11)

DOI: 10.1002/mco2.71024 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Viral diseases remain a major global health challenge despite substantial advances in vaccination, antiviral therapeutics, and public‐health interventions. However, current antiviral strategies are still constrained by important gaps, including rapid viral evolution, limited broad‐spectrum efficacy, immune escape, antiviral resistance, incomplete durability of protection, and inequitable global access to prevention and treatment. This review provides a comprehensive and integrated overview of contemporary antiviral prevention and therapeutic strategies, spanning vaccines, monoclonal antibodies, direct‐acting antivirals, host‐targeted therapies, immunomodulators, RNA‐based therapeutics, gene‐editing technologies, and cellular immunotherapies. We discuss the mechanistic foundations, clinical applications, pharmacologic considerations, and translational challenges associated with each modality across major human viral pathogens, including HIV, HBV, HCV, influenza, SARS‐CoV‐2, RSV, Ebola virus, arboviruses, and herpesviruses. Particular emphasis is placed on emerging innovations such as long‐acting prophylaxis, Fc‐engineered monoclonal antibodies, nanoparticle and mucosal vaccine platforms, CRISPR‐based antiviral systems, and broadly protective host‐directed approaches designed to overcome resistance and enhance pandemic preparedness. In addition, we highlight the growing importance of real‐time genomic surveillance and equitable global deployment strategies in shaping future antiviral responses, collectively underscoring that the next generation of antiviral medicine will depend on the convergence of universal immunization strategies, durable therapeutics, precision immune modulation, and rapidly deployable platform technologies capable of addressing both endemic and emerging viral threats.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →